Company: NCEL
Filing Date: 2025-06-09
Form Type: F-4/A
Source: 0001213900-25-052354
Chunk: 439

Company: NewcelX Ltd.
Filing Date: 2025-06-09
Form: F-4/A
Chunk 439
---
 Biochemistry, at the Weizmann Institute of Science. In January 1968, he was appointed at the Weizmann Institute of Science, Rehovot, Israel, where he has been a full -timeProfessor since January 1973, heading for several periods the Departments of Virology and of Molecular Genetics. His research on Interferon, its mechanisms of action and the isolation of the human Interferon -betagene, have led to the development of Interferon -betatherapy for the treatment of multiple sclerosis, Rebif®, Blockbuster drug marketed worldwide which was later sold to Merck Serono. In recent years, Prof. Revel’s laboratory focused on hESC and succeeded to produce nerve myelinating cells that, when transplanted in myelin -deficientanimals, have regenerated the myelin coating. These studies contributed to the development of a suspension culture technology for hESC which can then be used to produce differentiated human cells such as insulin -producingpancreatic beta cells and nerve myelinating cells. Alongside his research and development activity, Prof. Revel is deeply involved in the ethics of science and biotechnology, and served as chairman of the Israel National Bioethics Council and was a member of the International Bioethics Committee of UNESCO. Prof. Revel was the recipient of the Israel Prize for medical research, the EMET

249 Prize for biotechnology, and is a member of the Israel Academy of Science and Humanities. He has been a member of Israel’s National Committee for Biotechnology, serving for three years as its chairman. Professor Revel holds M.D. and Ph.D. degrees from the University of Strasbourg, France. Kfir Molakandov PhD, Vice President Research and Development Dr. Kfir Molakandov has served as Vice President, Head of Research and Development at Kadimastem since January 2018, and was previously a researcher at Kadimastem from January 2011 until December 2017. He received his B.A, M.Sc. in Cell and Gene Therapy for Diabetes and Ph.D. in Cell Therapy for Diabetes from the Tel Aviv University. Uri Ben Or, Chief Financial Officer Mr.Uri BenOr has served as Kadimastem’s Chief Financial Officer since June 2022 and its controller since its inception in 2010. Uri Ben Or brings over twenty -fiveyears of broad experience in corporate finance, accounting, M&A transactions, and IPOs. He has significant expertise, including serving as chief executive